StrideBio

Executive Summary

StrideBio is a privately held biotechnology company pioneering next-generation gene therapies through its proprietary STRIVE platform, which engineers adeno-associated virus (AAV) vectors to overcome key limitations of conventional vectors, including immunogenicity and lack of tissue specificity. Founded in 2015 and headquartered in Durham, North Carolina, the company focuses on developing treatments for severe genetic disorders affecting the central nervous system (CNS), cardiovascular system, and liver. By leveraging directed evolution and rational design, STRIVE enables the creation of novel AAV capsids with enhanced tropism, reduced immune recognition, and improved transduction efficiency, potentially broadening the therapeutic index and patient reach of gene therapy. StrideBio's initial pipeline targets indications with high unmet medical need, though specific programs remain undisclosed at this stage. The company's platform-centric approach positions it as a potential enabler for both internal programs and external partnerships, with the goal of addressing fundamental delivery challenges that have limited the clinical success of gene therapies.

Upcoming Catalysts (preview)

• Q4 2026Preclinical data readout for lead CNS program70% success
• H1 2027First IND filing for a cardiovascular indication50% success
• Q3 2026Establishment of strategic partnership for platform licensing40% success